Is now a good time to buy Nvidia? — Transcript
Full transcript
- 0:00Nvidia is actually regaining some of its
- 0:02losses in the pre-market after Wong's
- 0:04resignation yesterday. So joining us now
- 0:06to give us his take on the recent market
- 0:08news is Paul McDonald, chief investment
- 0:10officer at Harvest ETFs. Good morning.
- 0:12Great to have you join us.
- 0:14>> Good morning, Lindsay. Thanks for having
- 0:16me.
- 0:16>> It's been another interesting week. I
- 0:17wonder what impact do you expect the
- 0:19resignation of Jensen Wong to have on
- 0:21the broader tech industry?
- 0:24>> So look, I I think the tech sector has
- 0:26been really caught up in a bit of a a
- 0:28consolidation period anyway. If you look
- 0:30from June to today, it's really been
- 0:33oscillating back and forth.
- 0:36And so I think the the shorter term
- 0:38impact of the blue wave, you know,
- 0:40really driving concerns over AI
- 0:42infrastructure and data center build
- 0:44out,
- 0:45we think that's actually just the
- 0:47passing of the event.
- 0:48And so for for Nvidia particularly,
- 0:52it's not the first time a CEO and a
- 0:55visionary leader has stepped down and
- 0:58for controversial reasons either. So
- 1:01again, we would look at this as somewhat
- 1:03of a passing of an event and we see this
- 1:05actually as an opportunity specifically
- 1:08in an Nvidia.
- 1:10>> Yeah, I want to ask you more about that
- 1:11because you say that as you say, this is
- 1:12a good buying opportunity because the
- 1:14company still has good fundamentals. But
- 1:15like how concerned are you that the man
- 1:17who orchestrated a lot of the AI build
- 1:19out, who was the big voice behind it,
- 1:21will no longer be running the company?
- 1:22It sounds as though you say this has
- 1:24happened before in other companies and
- 1:25and we're just expected to see it happen
- 1:27again here.
- 1:29>> That would be our view. And look, there
- 1:30there's still some uncertainty around,
- 1:32you know, what what does this look like
- 1:34with, you know, chips being sent over to
- 1:36China? That's the unknown.
- 1:39I look back to times like with Steve
- 1:41Jobs and then to Tim Cook, you know, now
- 1:43driving Apple into one of the dominant
- 1:45players.
- 1:46And so again, some volatility in the
- 1:49shorter term. But look, Nvidia has a
- 1:52major problem in front of it is it has
- 1:55too much demand for its product. Demand
- 1:57is far exceeding supply. They've a
- 2:00trillion dollars of backlog
- 2:03purchases as we look out through 2027
- 2:06and 2028. They're, you know, depending
- 2:08on your source, they're 80% of the
- 2:11overall
- 2:12AI accelerator
- 2:14chip demand. And so, you know, from our
- 2:17perspective, you got a high growth stock
- 2:20that is actually trading at a value
- 2:22multiple. So November 17th is when they
- 2:25when they report earnings.
- 2:27And so our PM was looking at it
- 2:29yesterday and certainly we saw that
- 2:31pullback yesterday to, you know, mid
- 2:34teen
- 2:35forward earnings multiples, you know,
- 2:37somewhat unprecedented. And if you
- 2:39actually start to see any signs that the
- 2:42earnings are going to continue, it's you
- 2:44could easily see a 5x multiple back to
- 2:47where it was trading two weeks ago,
- 2:49which would put that up, you know, a $50
- 2:51movement in the stock. So we were quite
- 2:54constructive on NVIDIA in particular
- 2:57yesterday. We're we're adding to it
- 2:58within our HHIS portfolio.
- 3:00>> Okay. All right. So as you mentioned,
- 3:02NVIDIA reporting next week, but we're
- 3:04also watching Anthropic which is
- 3:05expected to to go public at some point
- 3:07next week. It's interesting timing now
- 3:09for Anthropic to to kind of make this
- 3:11decision to go public. How do you see
- 3:13that kind of rolling out and is that
- 3:15still maybe a good decision by this
- 3:16company?
- 3:18>> Oh, I think so. I saw last night the the
- 3:21IPO is 6x oversubscribed. There is a
- 3:24huge amount of demand for it just as
- 3:26cloud.
- 3:27And so
- 3:29we actually we were talking about it on
- 3:30the desk that there might even be a
- 3:32little bit of a turnover in the in the
- 3:34tech space right now as as a source of
- 3:36capital
- 3:38for the Anthropic IPO. And so
- 3:41we'll we'll see how that trades. You
- 3:43know, we have a single stock suite of of
- 3:45ETFs.
- 3:47We we did one on SpaceX and
- 3:49we have filed for Anthropic. I can
- 3:51assure everyone that it is going to be a
- 3:53volatile first trading day as we've
- 3:56experienced in these mega IPOs in the
- 3:58past. So we could see some actual
- 4:00pullback on some of the other tech or
- 4:02sources of of capital being um you know
- 4:06selling perhaps even some Nvidia uh this
- 4:09past week as the you know for that IPO.
- 4:13Uh so look we're excited to see it uh
- 4:15and uh we don't think that it's going to
- 4:17be anything I don't think their timing
- 4:19is bad at all and in fact uh from the
- 4:21investor's perspective on looking at the
- 4:24tech sector we actually see this
- 4:26pullback you know over the past past
- 4:29couple of months as an opportunity as we
- 4:32look out to 2027. Even though rotation
- 4:34has happened under the surface uh we
- 4:37still see tech as leadership and the
- 4:38cycle still continuing.
- 4:40>> Hm. Okay so we've been talking a lot
- 4:42about tech today but healthcare is
- 4:43actually a sector that you're really
- 4:44focused on right now. We'll go through
- 4:46some specific names in a moment but just
- 4:48first off what is it that you like about
- 4:49this sector at the moment?
- 4:51>> So so look medium long-term fundamentals
- 4:53don't change for us. Aging populations,
- 4:55developing markets, tech innovation. Uh
- 4:58so when we talk about the market and
- 5:00that leadership you know everybody says
- 5:03oh the market is just it's all AI AI and
- 5:05the bears have the microphone right now.
- 5:07We're 3% off all-time highs with you
- 5:10know 15% EPS growth for the broader
- 5:12market next year. But if you look at
- 5:14what the best performing sectors this
- 5:16year are year to date you know X Energy
- 5:20for obvious reasons you've got
- 5:22healthcare as number two. You've got
- 5:24staples, you've got utilities, you've
- 5:26got industrials. 10 out of 11 sectors
- 5:28are positive. The breadth has been
- 5:29expanding and rotation has been
- 5:31happening. And so when I look at what's
- 5:33happened in healthcare in particular in
- 5:36the shorter term everybody was on the
- 5:38tech side of the boat. We've seen that
- 5:40rotation happening but when I look at
- 5:422027 earnings forecasts have healthcare
- 5:46as the second highest growth for 2027.
- 5:49That excites us in an area that has some
- 5:51structurally long-term positives.
- 5:53>> And a specific name that's exciting you
- 5:55right now is Boston Scientific. This is
- 5:56one of your first picks for today. Tell
- 5:58us more about why you like this company.
- 6:00>> Well I I don't want to get overly
- 6:01excited. I I think this is exactly this
- 6:04is exactly
- 6:04>> Cautiously optimistic.
- 6:06>> Cautiously optimistic. And so I
- 6:08typically am
- 6:09and we are the horse before the cart
- 6:12investors. And so we would like to see
- 6:15some reacceleration in operating
- 6:17momentum. But we see a stock from a
- 6:20technical basis that has been
- 6:22consolidating for the better part of
- 6:24seven months off a very meaningful
- 6:26pullback. Uh they had some structural
- 6:29issues with competition. They had a
- 6:31cyber attack which we hope and expect it
- 6:34to be transitory. But we've also had at
- 6:37the same time as some some competition
- 6:39causing some margin compression and
- 6:41earnings uh compression. We've had the
- 6:44multiple for the company
- 6:46basically cut in half.
- 6:48And so if we start to see and really
- 6:51this is um you know when I think about
- 6:53the time of year on what stocks are down
- 6:55and where tax loss selling may occur,
- 6:59this is a name that we'd be looking for
- 7:00some
- 7:01capitulatory signs of tax loss selling
- 7:05abating in what has historically been a
- 7:07leading medtech.
- 7:08>> Hm. Okay. Uh I'm not sure maybe whether
- 7:11you're excited about this next one or
- 7:13again cautiously optimistic. Stryker is
- 7:15your next pick for today. Tell us more
- 7:16about this company.
- 7:17>> Again just keeping on that my primary
- 7:19sector is healthcare. If you had asked
- 7:21me at the start of the year what was
- 7:23going to be our best performing
- 7:25uh in that area, I would not have said
- 7:27uh you know companies like Merck on the
- 7:29large pharma side. So important to have
- 7:31diversity, but we tend to favor the
- 7:33medtechs right now. And I would say
- 7:35Stryker fully diversified, um solid
- 7:39growth, just a wonderful company. Uh
- 7:42they did have some in their orthopedics
- 7:44in their hips and knees, a little bit of
- 7:46uh of slowing demand of course and
- 7:48that's driven by some of the
- 7:49inflationary pressures and and the
- 7:51consumer that that has slowed. We see
- 7:53that as as transient in the area that is
- 7:56is really deferring demand. It's not
- 7:58like it's demand that is going away. You
- 8:00will still need to get those uh
- 8:02surgeries. And of course when we think
- 8:04about these types of companies and
- 8:06barriers to entry, areas like robotic
- 8:08assisted surgery with their with their
- 8:10make-over robotic systems. You know,
- 8:12this this is a company that is
- 8:14positioned for
- 8:16benefiting from a lot of those
- 8:17structural trends I was talking about
- 8:19over the medium term. So a great way to
- 8:20be in med tech, but also a diversified
- 8:24business lines.
- 8:25>> Mhm. And then United Health, that's
- 8:26another company like right now. Tell us
- 8:28about that one.
- 8:29>> Yeah, a little bit of a theme in and
- 8:30around the the blue wave where we see
- 8:32the Affordable Care Act, some of the
- 8:34credits that have
- 8:36uh and tax incentives. We could see more
- 8:38people come back onto exchanges and
- 8:41perhaps that causes some of the premiums
- 8:44that United Health would would receive
- 8:46on their insurance business. But the
- 8:48flip side of that is the propensity for
- 8:50more people coming into uh and and
- 8:54regaining insurance over the call of the
- 8:56next two years. Uh that that is a
- 8:58possibility. So a potential benefactor
- 9:01uh in the very short term from from the
- 9:03blue wave. However, that would be a very
- 9:07short-term perspective. The medium
- 9:09longer term structurally benefits from
- 9:12the those longer term thematics. And you
- 9:14know, a company that I did have some
- 9:16pressures over, call it about 18 months
- 9:18ago that were you know, we see them as
- 9:21transient. The market appears to seems
- 9:23to see they they were transient as well
- 9:25as we start to look out at
- 9:27re-accelerating growth in through 2027.
- 9:29So great quality core staple
- 9:32health insurer.
- 9:34>> Okay, and we actually do have time to go
- 9:35over your last pick as well. This is
- 9:37another healthcare company. Ab AbbVie,
- 9:40is that how you pronounce this one?
- 9:41>> Yeah, AbbVie. So again, wonderful. I'm
- 9:44delighted we were able to talk about it
- 9:45to get a to get a
- 9:48a little bit of diversity because in
- 9:49this sector diversity is exceptionally
- 9:52important. So AbbVie has done a
- 9:54wonderful job
- 9:56diversifying their
- 9:58their biotech biotech drugs and it's a
- 10:01large cap biotech company. And people
- 10:03might remember Humira
- 10:05used for a multitude of immunological
- 10:09uh
- 10:10And so that that went off patent. The
- 10:12company was able to uh really
- 10:15build off of that with their sky sky
- 10:19Renvoke drugs and reaccelerate the
- 10:22actual top line and bottom line growth.
- 10:25Uh and that really of course when you
- 10:26have these companies that you
- 10:27everybody's worried about a patent
- 10:29cliff, but then they're able to really
- 10:31build out and show reaccelerate
- 10:33reaccelerating growth. The markets
- 10:35rewarded them with some multiple
- 10:37expansion. We expect that to continue.
- 10:38Of course, it is a very well diversified
- 10:41uh company and people might know some of
- 10:43their other drugs such as Botox and
- 10:45other aesthetics. Uh but we like a solid
- 10:48company, reasonable valuation, uh decent
- 10:51dividend yield. It's been a core for us
- 10:53for uh for almost a decade now.
- 10:55>> Just before I let you go, I'm curious.
- 10:57The we talked about all the
- 10:58opportunities you see in the areas you
- 10:59like. Is there anything you're staying
- 11:01away from right now?
- 11:03>> I look I I think we want to be we want
- 11:05to be invested. I think we have to be
- 11:08allocating to some of the higher growth
- 11:10areas on this uh on this pullback. Um
- 11:14and so within within some of those areas
- 11:17of you know we talk a little bit about
- 11:19tech, but there's other areas in some of
- 11:21the higher growth that I continue to
- 11:23like, but I want to be focused in on
- 11:26some of the areas that you know are have
- 11:28defensive characteristics as well. So
- 11:30utilities look uh look quite promising.
- 11:33So I would say within those spaces some
- 11:36of the telecoms still need to turn
- 11:38through uh and and you know kind of
- 11:40stabilize here. Uh and so as we look out
- 11:44through 2020 seven, I would say being
- 11:47invested is primary. Uh and from from a
- 11:50risk perspective being diversified is is
- 11:53essential because the market is we are
- 11:55in the mid later cycle. So keeping uh
- 11:57keeping diversity in in focus I think is
- 11:59really important.
- 12:00>> Okay. All right. We'll leave it there.
- 12:02Paul McDonald, Chief Investment Officer
- 12:03at Harvest ETFs. Really appreciate your
- 12:05time this morning. Thank you.
About this transcript
This page contains the full transcript of Is now a good time to buy Nvidia? by BNN Bloomberg, generated from the public captions YouTube serves with the video. The transcript has 2,212 words across 338 segments, with the original timestamps preserved so you can click any line to jump to that moment in the embedded player.
What you can do with it
Use the transcript to take notes, quote the speaker, build a study guide, generate a summary with ChatGPT or Claude via the YouTube Summary tool, or export it as a timed subtitle file with YouTube to SRT. You can also re-open it in the transcriber to choose a caption track available on the video.
Free YouTube transcript tool
YouTube2Text is a free YouTube transcript generator — no signup, no daily limit. Paste any YouTube link and get the full transcript instantly, with timestamps, click-to-jump, caption language selection, AI prompts for ChatGPT, Claude, and Gemini, and exports to TXT, SRT, VTT, or Markdown.